Moderna today announced the completion of its biologic license application to the Food and Drug Administration for its mRNA COVID-19 vaccine. The application comes with a request for priority review. Moderna since May has submitted data sections to the FDA on a rolling basis, the complete body of which reviewed its COVID-19 vaccine’s efficacy and safety in more than 30,000 U.S. phase 3 trial participants. Moderna says its final analysis indicates that its vaccine has a 93% efficacy, which persisted through six months after completion of a two-dose regimen.

Related News Articles

Headline
The Federal Communications Commission’s Wireline Competition Bureau yesterday committed $41 million in funding to 72 health care providers under Round 2 of its…
Headline
Adults with a disability are more likely than adults without one to report difficulty getting a COVID-19 vaccine, the Centers for Disease Control and…
Headline
The AHA today released the latest edition of the COVID-19 Snapshot, underscoring the persisting challenges facing hospitals and health systems during the…
Headline
The Department of Health and Human Services today announced workplace guidance on the Health Insurance Portability and Accountability Act’s applicability to…
Headline
The Centers for Disease Control and Prevention today urged clinicians to educate pregnant patients about the benefits and safety of COVID-19 vaccination; and…
Headline
The Health Resources and Services Administration has opened the portal for health care providers to apply through Oct. 26 for a portion of $25.5 billion in…